Comprehensive Stock Comparison
Compare Solesence, Inc. Common Stock (SLSN) vs Colgate-Palmolive Company (CL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SLSN | 40.4% revenue growth vs CL's 1.4% |
| Value | SLSN | Lower P/E (18.3x vs 25.7x) |
| Quality / Margins | CL | 10.5% net margin vs SLSN's 1.7% |
| Stability / Safety | CL | Beta 0.02 vs SLSN's 1.25 |
| Dividends | CL | 2.3% yield; 5-year raise streak; SLSN pays no meaningful dividend |
| Momentum (1Y) | CL | +11.0% vs SLSN's -54.8% |
| Efficiency (ROA) | CL | 13.0% ROA vs SLSN's 2.0%, ROIC 43.4% vs 15.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Solésence is a developer and manufacturer of mineral-based skincare and makeup products that provide environmental protection. It generates revenue primarily through contract manufacturing and technology licensing for global and indie beauty brands — leveraging its proprietary Active Stress Defense™ technology platform. The company's competitive advantage lies in its patented mineral-based formulations that offer clean, inclusive sun protection and anti-pollution benefits.
Colgate-Palmolive is a global consumer goods company that manufactures and sells oral care, personal care, home care, and pet nutrition products. It generates revenue primarily from its Oral, Personal and Home Care segment — which contributes roughly 85% of sales — and its Pet Nutrition segment, which makes up the remaining 15%. The company's competitive advantage lies in its powerful global brand portfolio, particularly the dominant Colgate brand in oral care, and its extensive distribution network reaching over 200 countries.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CL leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). SLSN leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
CL is the larger business by revenue, generating $20.4B annually — 328.0x SLSN's $62M. CL is the more profitable business, keeping 10.5% of every revenue dollar as net income compared to SLSN's 1.7%. On growth, CL holds the edge at +5.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SLSNSolesence, Inc. C… | CLColgate-Palmolive… |
|---|---|---|
| RevenueTrailing 12 months | $62M | $20.4B |
| EBITDAEarnings before interest/tax | $2M | $3.9B |
| Net IncomeAfter-tax profit | $1M | $2.1B |
| Free Cash FlowCash after capex | -$11M | $3.6B |
| Gross MarginGross profit ÷ Revenue | +24.8% | +60.1% |
| Operating MarginEBIT ÷ Revenue | +1.9% | +21.3% |
| Net MarginNet income ÷ Revenue | +1.7% | +10.5% |
| FCF MarginFCF ÷ Revenue | -18.0% | +17.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -13.5% | +5.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -150.0% | -105.1% |
Valuation Metrics
At 18.3x trailing earnings, SLSN trades at a 51% valuation discount to CL's 37.7x P/E. On an enterprise value basis, SLSN's 17.2x EV/EBITDA is more attractive than CL's 17.4x.
| Metric | SLSNSolesence, Inc. C… | CLColgate-Palmolive… |
|---|---|---|
| Market CapShares × price | $90M | $79.9B |
| Enterprise ValueMkt cap + debt − cash | $104M | $86.6B |
| Trailing P/EPrice ÷ TTM EPS | 18.29x | 37.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 25.66x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.19x | 17.40x |
| Price / SalesMarket cap ÷ Revenue | 1.72x | 3.92x |
| Price / BookPrice ÷ Book value/share | 5.57x | 220.31x |
| Price / FCFMarket cap ÷ FCF | — | 21.99x |
Profitability & Efficiency
CL delivers a 5.8% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $6 for SLSN. SLSN carries lower financial leverage with a 1.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to CL's 21.88x.
| Metric | SLSNSolesence, Inc. C… | CLColgate-Palmolive… |
|---|---|---|
| ROE (TTM)Return on equity | +6.2% | +5.8% |
| ROA (TTM)Return on assets | +2.0% | +13.0% |
| ROICReturn on invested capital | +15.3% | +43.4% |
| ROCEReturn on capital employed | +24.7% | +41.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 1.02x | 21.88x |
| Net DebtTotal debt minus cash | $14M | $6.7B |
| Cash & Equiv.Liquid assets | $1M | $1.3B |
| Total DebtShort + long-term debt | $15M | $8.0B |
| Interest CoverageEBIT ÷ Interest expense | 3.37x | 12.37x |
Total Returns (with DRIP)
A $10,000 investment in CL five years ago would be worth $14,394 today (with dividends reinvested), compared to $14,222 for SLSN. Over the past 12 months, CL leads with a +11.0% total return vs SLSN's -54.8%. The 3-year compound annual growth rate (CAGR) favors CL at 12.8% vs SLSN's -3.6% — a key indicator of consistent wealth creation.
| Metric | SLSNSolesence, Inc. C… | CLColgate-Palmolive… |
|---|---|---|
| YTD ReturnYear-to-date | -14.7% | +28.3% |
| 1-Year ReturnPast 12 months | -54.8% | +11.0% |
| 3-Year ReturnCumulative with dividends | -10.5% | +43.4% |
| 5-Year ReturnCumulative with dividends | +42.2% | +43.9% |
| 10-Year ReturnCumulative with dividends | +204.8% | +78.5% |
| CAGR (3Y)Annualised 3-year return | -3.6% | +12.8% |
Risk & Volatility
CL is the less volatile stock with a 0.02 beta — it tends to amplify market swings less than SLSN's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CL currently trades 99.0% from its 52-week high vs SLSN's 7.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SLSNSolesence, Inc. C… | CLColgate-Palmolive… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 0.02x |
| 52-Week HighHighest price in past year | $16.56 | $100.18 |
| 52-Week LowLowest price in past year | $1.15 | $74.55 |
| % of 52W HighCurrent price vs 52-week peak | +7.7% | +99.0% |
| RSI (14)Momentum oscillator 0–100 | 45.2 | 68.5 |
| Avg Volume (50D)Average daily shares traded | 28K | 5.7M |
Analyst Outlook
CL is the only dividend payer here at 2.27% yield — a key consideration for income-focused portfolios.
| Metric | SLSNSolesence, Inc. C… | CLColgate-Palmolive… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $92.45 |
| # AnalystsCovering analysts | — | 43 |
| Dividend YieldAnnual dividend ÷ price | — | +2.3% |
| Dividend StreakConsecutive years of raises | — | 5 |
| Dividend / ShareAnnual DPS | — | $2.25 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.5% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Solesence, Inc. Com… (SLSN) | 100 | 548.15 | +448.1% |
| Colgate-Palmolive C… (CL) | 100 | 126.85 | +26.8% |
Colgate-Palmolive C… (CL) returned +44% over 5 years vs Solesence, Inc. Com… (SLSN)'s +42%. A $10,000 investment in CL 5 years ago would be worth $14,394 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Solesence, Inc. Com… (SLSN) | $29M | $52M | +77.6% |
| Colgate-Palmolive C… (CL) | $15.2B | $20.4B | +34.1% |
Colgate-Palmolive Company's revenue grew from $15.2B (2016) to $20.4B (2025) — a 3.3% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Solesence, Inc. Com… (SLSN) | 7.9% | 8.1% | +2.8% |
| Colgate-Palmolive C… (CL) | 16.1% | 10.5% | -34.9% |
Colgate-Palmolive Company's net margin went from 16% (2016) to 10% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Colgate-Palmolive C… (CL) | 33.1 | 30 | -9.4% |
Colgate-Palmolive Company has traded in a 22x–37x P/E range over 9 years; current trailing P/E is ~38x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Solesence, Inc. Com… (SLSN) | 0.05 | 0.07 | +40.0% |
| Colgate-Palmolive C… (CL) | 2.72 | 2.63 | -3.3% |
Colgate-Palmolive Company's EPS grew from $2.72 (2016) to $2.63 (2025) — a -0% CAGR.
Chart 6Free Cash Flow — 5 Years
Solesence, Inc. Common Stock generated $-3M FCF in 2024 (-679% vs 2021). Colgate-Palmolive Company generated $4B FCF in 2025 (+32% vs 2021).
SLSN vs CL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SLSN or CL a better buy right now?
Solesence, Inc. Common Stock (SLSN) offers the better valuation at 18.3x trailing P/E, making it the more compelling value choice. Analysts rate Colgate-Palmolive Company (CL) a "Hold" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SLSN or CL?
On trailing P/E, Solesence, Inc. Common Stock (SLSN) is the cheapest at 18.3x versus Colgate-Palmolive Company at 37.7x.
03Which is the better long-term investment — SLSN or CL?
Over the past 5 years, Colgate-Palmolive Company (CL) delivered a total return of +43.9%, compared to +42.2% for Solesence, Inc. Common Stock (SLSN). A $10,000 investment in CL five years ago would be worth approximately $14K today (assuming dividends reinvested). Over 10 years, the gap is even starker: SLSN returned +204.8% versus CL's +78.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SLSN or CL?
By beta (market sensitivity over 5 years), Colgate-Palmolive Company (CL) is the lower-risk stock at 0.02β versus Solesence, Inc. Common Stock's 1.25β — meaning SLSN is approximately 7169% more volatile than CL relative to the S&P 500. On balance sheet safety, Solesence, Inc. Common Stock (SLSN) carries a lower debt/equity ratio of 102% versus 22% for Colgate-Palmolive Company — giving it more financial flexibility in a downturn.
05Which has better profit margins — SLSN or CL?
Colgate-Palmolive Company (CL) is the more profitable company, earning 10.5% net margin versus 8.1% for Solesence, Inc. Common Stock — meaning it keeps 10.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CL leads at 21.3% versus 9.8% for SLSN. At the gross margin level — before operating expenses — CL leads at 60.1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SLSN or CL?
In this comparison, CL (2.3% yield) pays a dividend. SLSN does not pay a meaningful dividend and should not be held primarily for income.
07Is SLSN or CL better for a retirement portfolio?
For long-horizon retirement investors, Colgate-Palmolive Company (CL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.02), 2.3% yield). Both have compounded well over 10 years (CL: +78.5%, SLSN: +204.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SLSN and CL?
Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. CL pays a dividend while SLSN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.